Journal of Cancer Prevention

eISSN 2288-3657
pISSN 2288-3649

Survival time, cumulative survival probability and log-rank test for the study population according to clinical and treatment characteristics of patients during six-year of follow-up (Kaplan–Meier method) of colorectal cancer patients in TASH

Variable Category Median survival (mo) (95% CI) 1-year survival 2-year survival 3-year survival 4-year survival 5-year survival Overall survival Log-rank test (P-value)
Primary site Colon 35.5 (28.5-37.6) 88.7 67.7 48.8 30.8 17.5 21.5 0.68
Rectum 33.1 (28.0-44.6) 93.2 66.8 44.2 33.7 23.1 -
Stage of cancer at diagnosisa Stage I -b 98.0 94.6 89.6 83.2 83.0 83.0 < 0.001
Stage II 37.6 (35.0-…) 97.2 82.3 60.8 45.4 22.7 22.7
Stage III 34.8 (27.2-38.0) 91.2 67.2 44.5 22.4 - -
Stage IV 22.7 (19.1-25.9) 81.6 46.6 20.9 8.6 - -
Grades of Differentiated 45.3 (38.3-61.0) 93.5 79.6 64.3 46.5 30.7 23.3 < 0.001
cancer Moderately differentiated 33.1 (27.0-36.6) 92.4 66.8 36.5 22.8 - -
Undifferentiated 23.1 (19.4-27.0) 83.5 47.1 24.2 11.7 8.7 8.7
Histologic Adenocarcinoma 36.7 (31.2-41.8) 91.5 68.0 51.8 37.1 26.2 21.8 0.020
mucinous carcinoma 29.3 (24.4-36.8) 86.4 65.7 38.2 9.3 - -
Signet-ring-cell carcinoma 30.7 (23.3-36.1) 85.3 64.5 21.5 7.2 - -
Treatment Radiotherapy alone 37.9 (34.8-…) 84.4 71.7 47.5 46.5 46.5 46.5 < 0.001
Surgical treatment alone - 89.0 71.9 50.3 50.3 50.3 50.3
Chemotherapy alone 27.2 (23.2-26.1) 87.3 60.7 30.3 24.3 - -
Surgery plus chemotherapy 37.6 (34.7-45.3) 91.6 70.4 55.0 36.4 18.2 -
Radiation as neo-adjuvant to surgery 36.8 (18.3-…) 96.4 60.0 46.8 37.4 - -
Radiation + surgery + chemotherapy 30.4 (25.9-36.6) 90.8 67.3 40.3 17.4 8.7 -
Didn’t receive treatment - - - - - - -

The total number of 621 subjects were selected from patients registered between January 1, 2013 and December 30, 2017 with follow-up until December 30, 2018. Values are presented as percent only. TASH, Tikur Anbessa Specialized Hospital. aAccording to American Joint Committee of Cancer. bIt means more than half of patients survived. Median survival time could not be calculated.

Journal of Cancer Prevention 2020;25:38~47 https://doi.org/10.15430/JCP.2020.25.1.38
© J Cancer Prev
Copyright © Korean Society of Cancer Prevention. / Powered by INFOrang Co., Ltd